Ligustroflavone

Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis[1][2][3].

Product Specifications

CAS Number

[260413-62-5]

Product Name Alternative

Nuezhenoside

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

CaSR; Mixed Lineage Kinase; RIP kinase; TGF-beta/Smad

Type

Natural Products

Related Pathways

Apoptosis; GPCR/G Protein; MAPK/ERK Pathway; Stem Cell/Wnt; TGF-beta/Smad

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology; Metabolic Disease; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ligustroflavone.html

Purity

99.90

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(C=C(C1=CC=C(O)C=C1)OC2=CC(O[C@H](O[C@H](CO[C@H](O[C@@H](C)[C@H](O)[C@H]3O)[C@@H]3O)[C@@H](O)[C@@H]4O)[C@@H]4O[C@@](O[C@@H](C)[C@H](O)[C@H]5O)([H])[C@@H]5O)=C6)C2=C6O

Molecular Formula

C33H40O18

Molecular Weight

724.66

Precautions

H302, H315, H319

References & Citations

[1]Feng R, et al. Protective Effects of Ligustroflavone, an Active Compound from Ligustrum lucidum, on Diabetes-Induced Osteoporosis in Mice: A Potential Candidate as Calcium-Sensing Receptor Antagonist. Am J Chin Med. 2019;47 (2) :457-476.|[2]Zhang YY, et al. Ligustroflavone reduces necroptosis in rat brain after ischemic stroke through targeting RIPK1/RIPK3/MLKL pathway. Naunyn Schmiedebergs Arch Pharmacol. 2019 Sep;392 (9) :1085-1095.|[3]Kang R, et al. Ligustroflavone ameliorates CCl4-induced liver fibrosis through down-regulating the TGF-β/Smad signaling pathway. Chin J Nat Med. 2021 Mar;19 (3) :170-180.